Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Article in Chinese | WPRIM | ID: wpr-888085

ABSTRACT

This study aimed to explore the mechanism of Xiaoyao San(XYS) in the treatment of three diseases of liver depression and spleen deficiency, ie, depression, breast hyperplasia, and functional dyspepsia, and to provide a theoretical basis for the interpretation of the scientific connotation of "treating different diseases with the same method" of traditional Chinese medicines. Traditional Chinese medicine systems pharmacology database and analysis platform(TCMSP) was used to screen the active components of XYS which underwent principal component analysis(PCA) with the available drugs for these three diseases to determine the corresponding biological activities. The targets of XYS on depression, breast hyperplasia, and functional dyspepsia were obtained from GeneCards, TTD, CTD, and DrugBank databases. Cytoscape was used to plot the "individual herbal medicine-active components-potential targets" network. The resulting key targets were subjected to Kyoto encyclopedia of genes and genomes(KEGG) pathway analysis and gene ontology(GO) enrichment analysis. A total of 121 active components of XYS and 38 common targets in the treatment of depression, breast hyperplasia, and functional dyspepsia were collected. The key biological pathways were identified, including advanced glycation and products(AGEs)-receptor for advanced glycation and products(RAGE) signaling pathway in diabetic complications, HIF-1 signaling pathway, and cancer-related pathways. The key targets of XYS in the treatment of depression, breast hyperplasia, and functional dyspepsia included IL6, IL4, and TNF, and the key components were kaempferol, quercetin, aloe-emodin, etc. As revealed by the molecular docking, a strong affinity was observed between the key components and the key targets, which confirmed the results. The therapeutic efficacy of XYS in the treatment of diseases of liver depression and spleen deficiency was presumedly achieved by reducing the inflammatory reactions. The current findings are expected to provide novel research ideas and approaches to classify the scientific connotation of "treating different diseases with the same method" of Chinese medicines, as well as a theoretical basis for understanding the mechanism of XYS and exploring its clinical applications.


Subject(s)
Depression/drug therapy , Drugs, Chinese Herbal/pharmacology , Dyspepsia/drug therapy , Humans , Hyperplasia/drug therapy , Medicine, Chinese Traditional , Molecular Docking Simulation
2.
Arq. bras. cardiol ; 115(4): 630-636, out. 2020. graf
Article in Portuguese | SES-SP, LILACS, SES-SP | ID: biblio-1131353

ABSTRACT

Resumo Fundamento: A taxa de falha de enxerto de veia safena um ano após a cirurgia de revascularização do miocárdio varia de 10% a 25%. O objetivo deste estudo foi de investigar se a atorvastatina pode reduzir o acúmulo de células musculares lisas vasculares para inibir a hiperplasia intimal por meio da inibição da via p38 MAPK. Métodos: Quarenta e cinco ratos Sprague-Dawley foram randomizados em três grupos. Trinta ratos foram submetidos à cirurgia de enxerto de veia e randomizados para tratamento com veículo ou atorvastatina; quinze ratos foram submetidos à cirurgia sham. Detectamos a hiperplasia intimal por meio de coloração com hematoxilina-eosina e a expressão de proteínas relacionadas por meio de análise imuno-histoquímica e Western blot. Foram realizadas as comparações por análise de variância de fator único e pelo teste da diferença mínima significativa de Fisher, com p < 0,05 considerado significativo. Resultados: A íntima analisada pela coloração com hematoxilina-eosina era dramaticamente mais espessa no grupo controle que no grupo atorvastatina e no grupo sham (p < 0,01). Os resultados da coloração imuno-histoquímica de α-SMA demonstraram que a porcentagem de células positivas para α-SMA no grupo controle era mais alta que no grupo atorvastatina (p < 0,01). Nós também avaliamos α-SMA, PCNA, p38 MAPK e fosforilação de p38 MAPK após o tratamento com estatina por meio de análise de Western blot e os resultados indicaram que a atorvastatina não levou à redução de p38 MAPK (p < 0,05); no entanto, resultou na inibição da fosforilação de p38 MAPK (p < 0,01) e reduziu significativamente os níveis de α-SMA e PCNA, em comparação com o grupo controle (p < 0,01). Conclusão: Nós demonstramos que a atorvastatina pode inibir o acúmulo de células musculares lisas vasculares por meio da inibição da via p38 MAPK e é capaz de inibir a hiperplasia intimal em modelos de enxerto de veia em ratos.


Abstract Background: The rate of saphenous vein graft failure one year after coronary artery bypass grafting ranges from 10% to 25%. The aim of this study was to explore whether atorvastatin can reduce accumulation of vascular smooth muscle cells to inhibit intimal hyperplasia via p38 MAPK pathway inhibition. Methods: Forty-five Sprague-Dawley rats were randomized to three groups. Thirty rats received a vein graft operation, and they were randomized to be treated with vehicle or atorvastatin; fifteen rats received a sham operation. We detected intimal hyperplasia by hematoxylin-eosin staining and related protein expression by immunohistochemical and Western blot analysis. Comparisons were analyzed by single-factor analysis of variance and Fisher's least significant difference test, with p < 0.05 considered significant. Results: The intima analyzed by hematoxylin-eosin staining was dramatically thicker in the control group than in the atorvastatin group and sham group (p < 0.01). The outcomes of immunohistochemical staining of α-SMA demonstrated that the percentage of α-SMA-positive cells in the control group was higher than in the atorvastatin group (p < 0.01). We also evaluated α-SMA, PCNA, p38 MAPK, and phosphorylation of p38 MAPK after statin treatment by Western blot analysis, and the results indicated that atorvastatin did not lead to p38 MAPK reduction (p < 0.05); it did, however, result in inhibition of p38 MAPK phosphorylation (p < 0.01), and it significantly reduced α-SMA and PCNA levels, in comparison with the control group (p < 0.01). Conclusion: We have demonstrated that atorvastatin can inhibit accumulation of vascular smooth muscle cells by inhibiting the p38 MAPK pathway, and it is capable of inhibiting intimal hyperplasia in a rat vein graft model.


Subject(s)
Animals , Rats , Transplants , p38 Mitogen-Activated Protein Kinases , Veins , Rats, Sprague-Dawley , Atorvastatin/therapeutic use , Atorvastatin/pharmacology , Hyperplasia/prevention & control , Hyperplasia/drug therapy , Muscle, Smooth, Vascular
4.
Acta cir. bras ; 34(6): e201900607, 2019. tab, graf
Article in English | LILACS | ID: biblio-1019264

ABSTRACT

Abstract Purpose Coleus forskohlii Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatectomized rats. Methods The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg Coleus forskohlii/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively. Results No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected. Conclusion Treatment with Coleus forskohlii did not interfere with the course of hepatic hyperplasia.


Subject(s)
Animals , Male , Rats , Plant Extracts/administration & dosage , Plectranthus/chemistry , Hepatectomy/methods , Liver/pathology , Aspartate Aminotransferases/blood , Biomarkers/blood , Hepatocytes/drug effects , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Hyperplasia/drug therapy , Liver/surgery , Liver/drug effects
5.
An. bras. dermatol ; 90(2): 211-215, Mar-Apr/2015. tab, graf
Article in English | LILACS | ID: lil-741061

ABSTRACT

The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later. The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment, the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus, the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under study.


Subject(s)
Adult , Female , Humans , Dermatologic Agents/therapeutic use , Isotretinoin/therapeutic use , Sebaceous Gland Diseases/drug therapy , Sebaceous Glands/pathology , Hyperplasia/drug therapy , Statistics, Nonparametric , Skin/drug effects , Time Factors , Treatment Outcome
6.
Yonsei Medical Journal ; : 823-831, 2010.
Article in English | WPRIM | ID: wpr-72900

ABSTRACT

PURPOSE: Previous studies suggested that asymmetric stent expansion did not affect suppression of neointimal hyperplasia (NIH) after sirolimus-eluting stents (SES) implantation. The aim of this study was to evaluate the effects of stent eccentricity (SE) on NIH between SES versus paclitaxel-eluting stents (PES) using an intravascular ultrasound (IVUS) analysis from the randomized trial. MATERIALS AND METHODS: Serial IVUS data were obtained from Post-stent Optimal Expansion (POET) trial, allocated randomly to SES or PES. Three different SE (minimum stent diameter divided by maximum stent diameter) were evaluated; SE at the lesion site with maximal %NIH area (SE-NIH), SE at the minimal stent CSA [SE-minimal stent area (SE-MSA)], and averaged SE through the entire stent (SE-mean). We classified each drug-eluting stents (DES) into the concentric (> or = mean SE) and eccentric groups (< mean SE) based on the mean value of SE. RESULTS: Among 301 enrolled patients, 233 patients [SES (n = 108), PES (n = 125)] underwent a follow-up IVUS. There was no significant correlation between %NIH area and SE-NIH (r = - 0.083, p = 0.391) or SE-MSA (r = - 0.109, p = 0.259) of SES. However, SE-NIH of PES showed a weak but significant correlation with %NIH area (r = 0.269, p < 0.01). As to the associations between SE-mean and NIH volume index, SES revealed no significant correlation (r = - 0.001, p = 0.990), but PES showed a weak but significant correlation (r = 0.320, p < 0.01). However, there was no difference in the restenosis rate between the eccentric versus concentric groups of both DES. CONCLUSION: This study suggests that lower SE of both SES and PES, which means asymmetric stent expansion, may not be associated with increased NIH.


Subject(s)
Aged , Angiography/methods , Coronary Restenosis/pathology , Drug-Eluting Stents , Female , Humans , Hyperplasia/drug therapy , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Paclitaxel/administration & dosage , Sirolimus/administration & dosage , Tunica Intima , Ultrasonography, Interventional/methods
7.
Arq. bras. cardiol ; 86(4): 268-275, abr. 2006. tab, graf
Article in Portuguese | SES-SP, LILACS, SES-SP | ID: lil-426211

ABSTRACT

OBJETIVO: Avaliar a redução do volume de hiperplasia intimal após angioplastia com stents com sirolimus (Cypher®) comparados com os stents não-recobertos de estrutura metálica fina (Pixel®) em pacientes com vasos pequenos. MÉTODOS: Oitenta pacientes com doença arterial coronariana foram prospectivamente incluídos em duas séries consecutivas de tratamento, sendo a primeira empregando stents com sirolimus (50) e a segunda stents não-recobertos de estrutura metálica fina (30). RESULTADOS: Os resultados foram: menor porcentual de obstrução da prótese através do ultra-som intracoronário [5,0 por cento (EP = 0,77) x 39,0 por cento (EP = 4,72), p < 0,001], menor perda tardia intra-stent [0,25 mm (EP = 0,03) x 1,11 mm (EP = 0,13), p < 0,001] e no segmento do vaso [0,30 mm (EP = 0,04) x 0,83 mm (EP = 0,11), p < 0,001], e também menor reestenose intra-stent (0 por cento x 33,3 por cento, p < 0,001) e no segmento do vaso (4 por cento x 36,7 por cento, p < 0,001) com os stents com sirolimus. A sobrevivência livre de eventos foi de 96 por cento com os stents com sirolimus x 86,7 por cento com os stents não-recobertos (p = 0,190). CONCLUSÃO: Os pacientes com vasos de pequeno calibre após o implante de stents com sirolimus evoluem com menor hiperplasia intimal (menor porcentual de obstrução intra-stent e menor perda tardia) do que quando são utilizados stents não-recobertos de estrutura metálica fina. Isto resultou em redução significativa da reestenose angiográfica aos oito meses de evolução.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Stents , Angioplasty, Balloon, Coronary/methods , Antibiotics, Antineoplastic/administration & dosage , Coronary Stenosis/drug therapy , Sirolimus/administration & dosage , Tunica Intima/pathology , Angioplasty, Balloon, Coronary/standards , Coronary Stenosis/pathology , Prospective Studies , Hyperplasia/drug therapy , Hyperplasia/pathology , Drug Implants , Metals , Coronary Restenosis/prevention & control , Follow-Up Studies
8.
Braz. j. infect. dis ; 8(6): 465-468, Dec. 2004. ilus
Article in English | LILACS | ID: lil-401722

ABSTRACT

Tungiasis is caused by the penetration of the female sand flea Tunga penetrans into the epidermis, and subsequent hypertrophy of the parasite. In most cases lesions are confined to the feet. During a cross-sectional study, an unusual case of ectopic tungiasis in the inguinal area was detected. Histological examination of tissue samples showed a remarkable pseudoepitheliomatous aspect of the epidermis. Clinical features and differential diagnoses are discussed.


Subject(s)
Humans , Animals , Female , Child , Ectoparasitic Infestations/parasitology , Lymph Nodes/parasitology , Siphonaptera , Antinematodal Agents/therapeutic use , Cross-Sectional Studies , Ectoparasitic Infestations/drug therapy , Ectoparasitic Infestations/pathology , Hyperplasia/drug therapy , Hyperplasia/parasitology , Hyperplasia/pathology , Thiabendazole/therapeutic use
10.
Rev. chil. obstet. ginecol ; 63(5): 383-7, 1998. tab, graf
Article in Spanish | LILACS | ID: lil-243889

ABSTRACT

Se reporta 21 pacientes portadoras de hiperplasia de células escamosas de la vulva que fueron tratadas con corticoides tópicos entre 1988 y 1995. Observamos respuesta completa a los 2 meses de tratamiento en 47,6 por ciento de los casos. Un 95,8; 87,5 y 87,5 por ciento se mantuvieron libres de enfermedad al mes, 6 y 12 meses de seguimiento, respectivamente. La adherencia a tratamiento de mantención (a los seis meses) fue de 52,4 por ciento. Nuestros resultados avalan el uso de corticoesteroides tópicos en el tratamiento de la hiperplasia de células escamosas vulval


Subject(s)
Humans , Female , Adult , Middle Aged , Adrenal Cortex Hormones/pharmacology , Hyperplasia/drug therapy , Vulva/pathology , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Disease-Free Survival , Pruritus Vulvae/etiology , Retrospective Studies , Skin Diseases
11.
Acta gastroenterol. latinoam ; 26(4): 237-41, 1996. ilus, tab
Article in Spanish | LILACS | ID: lil-197176

ABSTRACT

La ectasia vascular del antro (EVA) o watermelon stomach (WS) es una causa poco frecuente de anemia o hemorragia digestiva alta manifesta en pacientes de edad avanzada. Presentamos 5 apcientes, todas mujeres, edad promedio 79 años, 4 anémicas de larga evolución y 1 con melena. Tres tenían endoscopía típica de WS, 2 tenían patente difusa. Las 5 con anatomía patológica positiva: ectasias vasculares y/o microtrombos fíbrinosos y proliferación fibromuscular en la l mina propria. La biopesia esdoscópica es tan fiel como el estudio de la pieza de antrectomía. Ninguna tenía hipertensión portal, aunque la EVA sería una entidad diferente a la gastropatía vascular del cirrótico. El tratamiento conssitió en electrocoagulación monopolar de las lesiones tras fracaso del tratamiento médico en 1 caso, corticoterpia mas ferroterapia en 3, mientras que el restante no requiere tratamiento por el momento. Conclusiones: la EVA debe tenerse presente en pacientes anémicos crónicos sien diagnóstico, de edad avanzada. Las im genes endoscópicas no siempre son las típicas del estómago en sandía (WS). Se debe biopsiar el antro gastrico ante la duda. Si no responden al tratamiento con corticoides y/o hierro, el tratamiento de elección es el laser o el "heat electrocoagulación monopolar o la esclerosis. La cirurgía es el último recurso a aplicar.


Subject(s)
Aged , Female , Humans , Anemia, Iron-Deficiency/etiology , Pyloric Antrum/blood supply , Vascular Diseases/diagnosis , Aged, 80 and over , Anemia, Iron-Deficiency/drug therapy , Biopsy , Chronic Disease , Electrocoagulation , Endoscopy, Digestive System , Follow-Up Studies , Hyperplasia/diagnosis , Hyperplasia/drug therapy , Hyperplasia/pathology , Iron/therapeutic use , Melena/diagnosis , Melena/drug therapy , Melena/etiology , Prednisolone/therapeutic use , Pyloric Antrum/pathology , Vascular Diseases/complications , Vascular Diseases/drug therapy
12.
Cir. Urug ; 64(4): 315-6, oct.-dic. 1994.
Article in Spanish | LILACS | ID: lil-182380

ABSTRACT

Se realizó un trabajo experimental en perros a efectos de comparar los efectos de la heparina cálcica y la enoxaparina sobre el desarrollo de hiperplasia intimal desarrollado en el Depto. Básico de Cirugía. No se encontraron diferencias significativas en el desarrollo del fenómeno analizado en las distintas series estudiadas con respecto al grupo control, por lo cual no se pudo poner en evidencia un efecto inhibidor sobre el desarrollo de hiperplasia intimal para ninguno de los fármacos estudiados.


Subject(s)
Animals , Dogs , Enoxaparin/therapeutic use , Heparin/therapeutic use , Hyperplasia/drug therapy , Tunica Intima/pathology , Vital Statistics
SELECTION OF CITATIONS
SEARCH DETAIL